Epcoritamab with or without lenalidomide and rituximab after CAR T
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding a drug called epcoritamab (with or without two other drugs, lenalidomide and rituximab) can help people with large B-cell lymphoma whose cancer was still detectable after CAR T-cell therapy. It aims to stop the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 or older.
- You have a type of lymphoma called large B-cell lymphoma that has come back or not responded to treatment.
- You have already received CAR T-cell therapy (a treatment that uses your own immune cells) for your lymphoma.
- A PET/CT scan between 25 and 100 days after CAR T showed your lymphoma got smaller or disappeared.
- A blood test between 25 and 100 days after CAR T showed that your cancer was still detectable at a very low level (MRD-positive).
- You are well enough to be up and about (ECOG score 0-2) and your heart, kidneys, and liver are working adequately.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immune therapies—epcoritamab (a bispecific antibody) and CAR T cells—for people with large B-cell lymphoma whose cancer didn't respond to first treatment. The goal is to see if this combination works better than CAR T cells alone.
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
This trial tests a new drug called epcoritamab for people whose large B-cell lymphoma has come back after or didn't fully respond to their first treatment. It's an option for those who cannot or choose not to have CAR-T therapy or a stem cell transplant.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
Hear when a new Relapsed/Refractory Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.